ACAnnick Clement

Annick Clement

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Annick Clement has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Brigitte Fauroux

    Departement de Pneumologie Pediatrique – INSERM E213, Hopital d’enfants Armand Trousseau, 26 Ave du Dr Arnold Netter, 75571 Paris cedex 12, France

    3 shared publications
  • Ralph Epaud

    Paediatric Department, Centre Hospitalier Intercommunal de Créteil, Reference Centre for Rare Lung Diseases (RespiRare®), University Paris Est Créteil, INSERM, IMRB , Créteil

    3 shared publications
  • Alexandra Henrion-Caude

    Departement de Pneumologie Pediatrique – INSERM E213, Hopital d’enfants Armand Trousseau, 26 Ave du Dr Arnold Netter, 75571 Paris cedex 12, France

    2 shared publications
  • Alice Hadchouel

    AP-HP, Hôpital Universitaire Necker-Enfants Malades, Service de Pneumologie Pédiatrique, Centre de Référence pour les Maladies Respiratoires Rares de l'Enfant, Paris, France

    2 shared publications
  • Candice Fabre

    Pediatric Pulmonology Department, University Timone Hospital for Children, AP-HM, Marseille, France

    2 shared publications
  • Caroline Perisson

    Pediatric Unit, University Hospital Sud Reunion, Saint-Pierre, France

    2 shared publications

Latest Publications

  • Long-term evolution of neuroendocrine cell hyperplasia of infancy: the FRENCHI findings

    by Morgane Dervaux, Caroline Thumerelle, Candice Fabre, Rola Abou-Taam, Tiphaine Bihouee, Jacques Brouard, Annick Clement, Christophe Delacourt, Céline Delestrain, Ralph Epaud, et al.

    Only few studies report long-term evolution of patients with neuroendocrine cell hyperplasia of infancy (NEHI). We report data from a 54-patient cohort followed up in the French network for rare respiratory diseases (RespiRare). Demographic characteristics and respiratory and nutritional evolution were collected at the time of the patient’s last scheduled visit. The mean duration of follow-up was 68 months (5 months to 18 years). Fifteen patients (27.8%) were considered clinically cured. During follow-up, hospitalizations for wheezy exacerbations were reported in 35 patients (55%), and asthma diagnosed in 20 (37%). Chest CT scan improvement was noted in 25/44 (56.8%). Spirometry showed a persistent obstructive syndrome in 8/27 (29.6%). A sleep disorder was rare (2/36, 5.5%). Oxygen weaning occurred in 28 of the 45 patients initially treated (62.2%) and was age-dependent (35.7% under 2 years, 70.5% between 2 and 6 years, and 100% after 7 years). Oxygen duration was linked to a biopsy-proven diagnosis (p = 0.02) and to the use of a nutritional support (p = 0.003). Corticosteroids were largely prescribed at diagnosis, with no evident respiratory or nutritional effect during follow-up. Among 23 patients with an initial failure to thrive, 12 (52.2%) had no weight recovery. Initial enteral feeding (17/54, 31.5%) was stopped at a mean age of 43 months (3 to 120), with no effect on cure and oxygen liberation at the last visit.   Conclusion: Our results show that NEHI has a globally positive, but unequal, improvement over time. Further prospective studies are needed to better clarify the different trajectories of patients with NEHI. What is Known: • Neuroendocrine cell hyperplasia of infancy (NEHI) is an interstitial lung disease whose long-term outcome is considered positive from very few studies including heterogeneous populations. What is New: • The 68-month follow-up of our 54-patient cohort showed respiratory/nutritional symptom persistence in 72.2%, oxygen requiring in 34%, and asthma in 37%. When controlled, radiological or functional improvement was noted in 56.8 and 40.7%. Further prospective studies are needed to better clarify the different trajectories of patients with NEHI.


  • French national cohort of neuroendocrine cell hyperplasia of infancy (FRENCHI) study: diagnosis and initial management

    by Candice Fabre, Caroline Thumerelle, Morgane Dervaux, Rola Abou-Taam, Tiphaine Bihouee, Jacques Brouard, Annick Clement, Christophe Delacourt, Céline Delestrain, Ralph Epaud, et al.

    Early diagnosis of neuroendocrine cell hyperplasia of infancy (NEHI) is crucial as, conversely to the other causes of intersititial lung disease, corticosteroids are not recommended. Diagnosis is historically based on lung biopsy (NEHI), but in current practice, a clinical and radiological approach is more and more preferred (NEHI syndrome). This national study aimed to address diagnosis and initial management of patients followed up for a NEHI pattern in pediatric centers for rare lung diseases (RespiRare, France). Data on neonatal and familial events, symptoms at diagnosis, explorations performed and results, and therapeutic management were collected by questionnaire. Fifty-four children were included (boys 63%). The mean onset of symptoms was 3.8 ± 2.6 months. The most frequent symptoms at diagnosis were tachypnea (100%), retraction (79.6%), crackles (66.7%), and hypoxemia (59.3%). The mean NEHI clinical score, evocative when ≥ 7/10, was 7.9 ± 1.4 (76% with a score ≥ 7). All chest CT-scans showed ground glass opacities evolving at least the middle lobe and the lingula. Lung biopsy was performed in 38.9% of the cases and was typical of NEHI in only 52.4%, even when the clinical presentation was typical. Initial treatments were oxygen (83.6%) and more curiously intravenous pulses of steroids (83.3%) and azithromycin (70.2%). Conclusion: This national cohort of patients underlines diagnosis difficulties of NEHI. A composite clinical and radiological score should help clinicians for limiting the use of anti-inflammatory drugs. What is Known: •Neuroendocrine cell hyperplasia of infancy (NEHI) is an interstitial lung disease whose diagnosis is essential to limit corticosteroids therapy. What is New: •In this national cohort of 54 patients with a NEHI pattern, diagnosis is mainly based on clinical symptoms and chest CT-scan results. The newly proposed clinical score and, when performed, the lung biopsies are faulted in 25 and 50% of the cases, respectively. •Corticosteroids are widely used. Such results plead for a new composite score to formally diagnose NEHI.


  • Task force on chronic interstitial lung disease in immunocompetent children

    by A. Clement, committee members

    Chronic interstitial lung diseases in children represent a heterogeneous group of disorders of both known and unknown causes that share common histological features. Despite many efforts these diseases continue to present clinical management dilemmas, principally because of their rare frequency that limits considerably the possibilities of collecting enough cases for clinical and research studies.Through a Task Force conducted by the European Respiratory Society, which comprised respiratory physicians and basic scientists from across Europe, 185 cases of interstitial lung diseases in immunocompetent children were collected and reviewed. The present report provides important clinically-relevant information on the current approach to diagnosis and management of chronic interstitial lung diseases in children. In addition, recommendations for the management of paediatric interstitial lung diseases, as well as new insights into interstitial lung diseases pathophysiology during childhood are discussed.


  • Guest editorial

    by Annick Clement, Brigitte Fauroux

  • The pathogenesis of interstitial lung diseases in children

    by Annick Clement, Alexandra Henrion-Caude, Brigitte Fauroux


    • 15 January 2003
      • Vol. 53  (2) , 163-6

    [Protein repair therapy in cystic fibrosis].

    by Annick Clément, Aline Tamalet, Brigitte Fauroux, Ralph Epaud

    In the past few years since the cloning of the gene defective in cystic fibrosis, much has been learned on the function of the protein cystic fibrosis transmembrane conductance regulator (CFTR) and on the mechanisms regulating its expression. Based on the current understanding of the processes involved in lung disease progression, a number of approaches have been developed using not only gene therapy, but also pharmacological agents. Several of these agents have been reported to restore function to CFTR with specific mutations.

  • Role of Cyclins in Epithelial Response to Oxidants

    by Annick Clement, Alexandra Henrion-Caude, Valerie Besnard, Sophie Corroyer

    Oxidants are involved in a large variety of pulmonary diseases. Among the various cell types that compose the respiratory system, the epithelial cells appear to be a major target for oxidative stress. When cells are exposed to DNA-damaging agents such as oxidants, a feedback control is activated that acts as a brake on the cell cycle to inhibit entry into the S phase until DNA repair is completed. Progression through the G1 phase and the G1–S transition involves sequential assembly and activation of key regulators of the cell cycle machinery, the cyclin-dependent kinases (CDKs). Activity of the CDKs is regulated by several mechanisms, which include the CDK inhibitors (CKIs). The CKI p21CIP1 appears to play an important role in the response of epithelial cells to oxidants.


  • Chronic interstitial lung disease in children: Response to high‐dose intravenous methylprednisolone pulses

    by Pascale Desmarquest, Aline Tamalet, Brigitte Fauroux, Michele Boule, Liliane Boccon‐Gibod, Guy Tournier, Annick Clement